Top Stories
The companies agreed to provide state Medicaid programmes access to most-favoured nation (MFN) drug prices on certain products.
AZD5462 showed encouraging effects on cardiovascular haemodynamic measures without major safety concerns in an early-stage trial.
Ipsoprubart, a pan-SIRP mAb, is in the registrational Phase II/III SURPASS trial for secondary haemophagocytic lymphohistiocytosis.
PharmaEssentia's long-acting interferon was first approved for polycythemia vera in 2021.
The PCSK9 inhibitor, one of Amgen's top-selling drugs, cut all-cause deaths in high-risk patients in the VESALIUS-CV trial.
Conference News
FirstWord will be speaking with a leading expert about AstraZeneca and Ionis' detailed data from the failed CARDIO-TTRansform trial, and how they will impact the battle between TTR silencers and stabilisers in the ATTR-CM space.
New data from Arrowhead Pharmaceuticals at this weekend's European Society of Cardiology (ESC) meeting furthered the case for Redemplo (plozasiran) in severe hypertriglyceridaemia, but may have weakened its argument for meaningful differentiation from Ionis' first-comer Tryngolza (olezarsen).
Key takeaways Metformin is commonly used to lower blood glucose levels in patients with type 2 diabetes. Whether metformin also has independent cardioprotective effects in patients with heart failure ...
Key takeaways Previously, the combination of hydralazine with isosorbide dinitrate was associated with reduced mortality in Black patients with heart failure and reduced ejection fraction. In the H-H...
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)2026 ESC/European Renal As...
